TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In a prospective study of 276 people with HPV-positive oropharyngeal cancer, a reduced-intensity radiation strategy was followed by five-year locoregional control of 97% and overall survival of 90.8%. The results support further study of the approach, but do not establish it as a standard of care; researchers say multicenter phase III confirmation is needed.
A prospective study of 276 patients with HPV-positive oropharyngeal cancer found that a reduced-intensity radiation strategy was followed by 97% five-year locoregional control and 90.8% overall survival, according to results reported in JAMA Oncology. The findings add long-term evidence for lowering radiation to elective lymph-node regions, but the researchers and an outside specialist say the regimen still needs testing in a multicenter phase III trial before it can be established as a standard approach.
Patients received definitive concurrent chemoradiation, with elective nodal irradiation (ENI) reduced to 30 Gy rather than the usual 50–60 Gy described in the report. The treatment also omitted selected low-risk nodal regions. Treated nodal and subclinical regions received 30 Gy in 15 fractions, followed by a sequential 40-Gy boost in 20 fractions. Most patients received intensity-modulated radiotherapy; 20 received intensity-modulated proton therapy.
After a median follow-up of five years, 260 patients had no evidence of disease at five years, and 250 were alive at last follow-up. Reported five-year outcomes included 97.0% locoregional control, 90.8% overall survival, 91.2% distant metastasis-free survival and 85.9% progression-free survival. The source report also said 94% of patients had no evidence of disease and 90.6% were alive at last follow-up; these figures refer to the study’s follow-up assessment, while the other figures are explicitly reported as five-year outcomes.
The investigators reported that no treatment failures occurred in omitted nodal basins. One elective nodal failure involved a contralateral lymph node that had been indeterminate on baseline imaging and received 30 Gy. Most locoregional recurrences occurred in areas with known residual macroscopic disease. The study was prospective, but the provided report does not describe it as a randomized comparison against standard-dose ENI.
Lower Nodal Doses, Lasting Control
The findings matter because elective radiation treats lymph-node areas that may harbor microscopic cancer even when they are not visibly involved. Reducing the dose and the volume treated could limit exposure to nearby normal structures involved in saliva production and swallowing, potentially reducing treatment burdens for patients. The study did not, however, provide quality-of-life results in this long-term report, so the size of any patient-experienced benefit cannot be determined from these data alone.
David Sher, a radiation oncologist at UT Southwestern Medical Center who was not involved in the research, told MedPage Today that ENI can contribute substantially to irradiation of normal tissue. He described the outcomes as notable given the dose reduction, while emphasizing that a multicenter randomized phase III study is needed to confirm non-inferiority. The results are evidence supporting further evaluation, not proof that lower-dose ENI is appropriate for every patient.
Products Worth Considering
Philips Sonicare ProtectiveClean 5300 Rechargeable Electric Toothbrush, Black, with 3 Brush Heads
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
Oral-B iO Series 5 Rechargeable Electric Toothbrush with 3 Brush Heads and Travel Case, Black
As an affiliate, we earn on qualifying purchases.
How the Study Reduced Radiation
The study builds on earlier reports from the same research group. Investigators led by Nancy Y. Lee of Memorial Sloan Kettering Cancer Center previously reported two-year outcomes for the strategy; the current analysis was intended to test whether cancer control remained durable over longer follow-up. The approach combined reduced-dose elective nodal treatment with definitive chemoradiation directed at the cancer.
Sher noted that participants underwent PET-CT imaging and that most also had MRI. He said imaging may help identify small lymph nodes that could contain cancer and need a higher radiation dose. Patients also received cisplatin-containing chemotherapy. The source report says the study adds to existing de-escalation evidence, including a prior phase III trial using a somewhat higher nodal radiation dose, but it does not provide details sufficient to compare trial populations or treatment outcomes directly.
“The degree of success is remarkable given the extent of dose reduction.”
— David Sher, UT Southwestern Medical Center, speaking to MedPage Today
Questions Before Routine Adoption
The report does not establish whether this regimen is non-inferior to standard-dose ENI in a randomized comparison. It also does not provide quality-of-life data for this long-term analysis, even though reduced exposure to normal tissue is a proposed benefit. Sher said the report did not state how many equivocal lymph nodes received a higher radiation dose, a detail that could help clinicians interpret how the strategy was applied.
The findings come from a defined study population treated with imaging and concurrent chemotherapy; they should not be assumed to apply to every person with HPV-positive throat cancer. The supplied material does not identify a confirmed phase III trial launch, enrollment timeline or eligibility criteria. Those details, along with how results compare across patient groups, remain unresolved.
Phase III Testing Is Needed
The next key step is a multicenter randomized phase III trial designed to determine whether the reduced-dose approach preserves cancer control compared with standard treatment. Sher said such a study would be needed to confirm non-inferiority across institutions. The source material does not say that a trial has opened or provide a start date, so its availability and timing remain unknown.
Until stronger comparative evidence is available, the reported outcomes are best understood as long-term support for further evaluation of de-escalated ENI—not as a universal treatment recommendation. Clinicians and patients will need trial results to assess how the regimen’s cancer-control outcomes and potential effects on treatment side effects balance for different cases.
Key Questions
What treatment approach did the study examine?
It examined definitive concurrent chemoradiation for HPV-positive oropharyngeal cancer with 30 Gy of elective nodal irradiation and omission of selected low-risk nodal regions. Treated areas also received a sequential boost, according to the report.
What were the five-year results?
The study reported 97.0% locoregional control, 90.8% overall survival, 91.2% distant metastasis-free survival and 85.9% progression-free survival at five years. These are outcomes for the study group, not a guarantee for an individual patient.
Did omitted lymph-node areas have treatment failures?
The investigators reported no failures in nodal basins that were omitted. One elective nodal failure occurred in a contralateral node that was indeterminate at baseline and received 30 Gy.
Does this establish lower-dose radiation as standard care?
No. The findings add long-term evidence, but the source report and outside specialist say a multicenter randomized phase III trial is needed to confirm non-inferiority before the approach can be established as a standard.
Source: medpagetoday.com
